Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study
Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK
Published in Nutrition Journal
Methodology
Randomized, double-blind, placebo-controlled 90-day pilot trial of B. coagulans MTCC 5856 in diarrhoea-predominant IBS.
Key Findings
Clinical symptom scores, bloating and stool frequency improved significantly versus placebo.
Conclusions
Spore-forming B. coagulans was effective and well tolerated in IBS-D over 90 days.
Limitations
Pilot size, manufacturer employees as authors, single strain.
Supplements Studied
Spore-forming B. coagulans was effective and well tolerated in IBS-D over 90 days.
Clinical symptom scores, bloating and stool frequency improved significantly versus placebo.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.